These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8905244)

  • 21. 6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine.
    Park BK; Eichelbaum M; Ohnhaus EE
    Br J Clin Pharmacol; 1982 May; 13(5):737-40. PubMed ID: 7082544
    [No Abstract]   [Full Text] [Related]  

  • 22. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.
    Klotz U; Mikus G; Zekorn C; Eichelbaum M
    Br J Clin Pharmacol; 1986 Nov; 22(5):618-20. PubMed ID: 3790411
    [No Abstract]   [Full Text] [Related]  

  • 26. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacogenetics of sparteine and debrisoquine.
    Inaba T; Vinks A; Otton SV; Kalow W
    Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
    Jurima M; Inaba T; Kalow W
    Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
    Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
    Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between paroxetine and the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
    Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
    Horai Y; Ishizaki T; Eichelbaum M; Hashimoto K; Chiba K; Dengler HJ
    Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid determination of sparteine and its metabolites in urine.
    Veningerová M; Prachar V; Lukácsová M; Glasa J; Holomán J
    J Chromatogr; 1993 Dec; 622(2):274-7. PubMed ID: 8150877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The polymorphism of pachycarpine oxidation].
    Piotrovskiĭ VK; Belolipetskaia VG; Rumiantsev DO; Metelitsa VI
    Eksp Klin Farmakol; 1992; 55(4):56-8. PubMed ID: 1458193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW; Moody DE
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 39. Benzo(a)pyrene metabolism in hepatic microsomes from female DA rats with a genetic sparteine oxidation deficiency.
    Schlede E; Roots I
    Toxicol Lett; 1985 Dec; 29(1):5-10. PubMed ID: 4082205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.